INMUNE BIO INC. UNDERWRITING AGREEMENTUnderwriting Agreement • July 16th, 2020 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 16th, 2019 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • Nevada
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 15, 2019, by and between INMUNE BIO INC., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 26th, 2024 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of April 24, 2024, between INmune Bio Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
PURCHASE AGREEMENTPurchase Agreement • May 16th, 2019 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • Nevada
PURCHASE AGREEMENT (the “Agreement”), dated as of May 15, 2019, by and between INMUNE BIO INC., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).
Inmune Bio Inc.Inmune Bio, Inc. • July 15th, 2021 • Biological products, (no disgnostic substances) • New York
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 24th, 2022 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 21, 2022, between INmune Bio, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 15th, 2021 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of July 13, 2021, and is between Inmune Bio, Inc, a corporation incorporated under the laws of the state of Nevada (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
WARRANT TO PURCHASE SHARES OF COMMON STOCK INMUNE BIO INC.Inmune Bio, Inc. • April 22nd, 2024 • Biological products, (no disgnostic substances) • New York
THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00pm (New York City time) on the earlier of (1) the two (2) year anniversary of the Initial Exercise Date or (2) thirty (30) Trading Days following the reporting of top line data (EMACC) in the Phase 2 Alzheimer’s program of XPro1595, (the “Termination Date”) but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company’s common stock, such officers, directors or affiliates will have an additional 60 days from the terminat
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 22nd, 2024 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2024, between INmune Bio Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
RIGHTS AGREEMENT by and between INmune bio, inc. and vstock transfer, llc, as Rights Agent, Dated as of December 30,2020Rights Agreement • January 4th, 2021 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • Nevada
RIGHTS AGREEMENT, dated as of December 30, 2020, (this “Agreement”), by and between INmune Bio, Inc., a Nevada corporation (the “Company”), and Vstock Transfer, LLC, as rights agent (the “Rights Agent”).
THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL,...Inmune Bio, Inc. • November 20th, 2018 • Biological products, (no disgnostic substances) • New York
THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO [●], 20[__] [DATE THAT IS 180 DAYS FROM THE EFFECTIVE DATE OF THE REGISTRATION STATEMENT]. VOID AFTER 5:00 P.M., EASTERN TIME, [●], 20[__] [DATE THAT IS FIVE YEARS AFTER THE EFFECTIVE DATE OF THE REGISTRATION STATEMENT].
ContractWarrant to Purchase Stock • June 15th, 2021 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 6.3 AND 6.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
At-the-market SALES AGREEMENTSales Agreement • March 11th, 2021 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
INmune Bio Inc., a Nevada corporation ( the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
INMUNE BIO INC. PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • November 20th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
Incentive Stock Option AgreementIncentive Stock Option Agreement • March 24th, 2022 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • Nevada
This Incentive Stock Option Agreement (this “Agreement”) is made and entered into as of March 21, 2022 by and between INmune Bio, Inc., a Nevada corporation (the “Company”) and (the “Participant”).
Employment AgreementEmployment Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
This Employment Agreement (the "Agreement") is made and entered into as of January 1, 2018 (the “Effective Date”), by and between Raymond Tesi MD, an individual (the "Executive"), and INmune Bio Inc., a Nevada corporation (the "Company").
INMUNE BIO, INC. Nonqualified Stock Option AgreementNonqualified Stock Option Agreement • March 24th, 2022 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
This NONQUALIFIED STOCK OPTION AGREEMENT (this “Agreement”), made and entered into on the 21st day of March 2022, by and between (the “Participant”) and INmune Bio, Inc., a Nevada corporation (the “Company”), sets forth the terms and conditions of stock options issued to the Participant by the Compensation Committee of the Board of Directors of the Company on March 21, 2022 (the “Grant Date”) pursuant to the Company's 2021 Stock Incentive Plan (the “Plan”) and this Agreement, which options have been approved by the Company’s Board of Directors. Any capitalized terms used but not defined herein shall have the meaning prescribed in Annex A or in the Plan.
INMUNE BIO INC. 2017 STOCK INCENTIVE PLAN Incentive Stock Option AgreementIncentive Stock Option Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
In the event that the Company is not publicly traded, the Participant may exercise this Option on a cashless basis by using the last price per share at which at least $500,000 of shares or the conversion price of securities convertible into Common Stock was offered at and sold.
CONSULTING AGREEMENTConsulting Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • California
THIS AGREEMENT, dated as of May 16, 2018, between Immune Bio, Inc., with offices located at 1224 Prospect Street, Suite 150, La Jolla, California 92037, a Nevada Corporation (the “Company”), Pacific Seaboard Investments Ltd., having its principal place of business at Suite # 404-999 Canada Place, Vancouver, BC., V6C 3E2 a British Columbia corporation or its designee(s)(“CONSULTANT”).
DATED 29th November 2017 - and - MATERIAL TRANSFER AND LICENCE AGREEMENTLicence Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
THIS MATERIAL TRANSFER AGREEMENT together with its Schedules, the "Agreement" is made on 29 November 2017 , the "Effective Date", between
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Agreement is made and entered into as of June 26, 2017 (“Effective Date”), by and between the University of Pittsburgh – Of the Commonwealth System of Higher Education, a non- profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania, with an office at 1st Floor Gardner Steel Conference Center, 130 Thackeray Avenue, Pittsburgh, Pennsylvania 15260 (“University”), and Immune Ventures, LLC, with its principal business at 7503 Jones Ave NW, Seattle, WA 98117 (“Licensee”).
INmune Bio Inc.Confidential Information and Invention Assignment Agreement • March 4th, 2021 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • Nevada
INmune Bio, Inc. (the “Company”) is pleased to offer you continued at-will employment in the position of Chief Financial Officer (“CFO”) on the terms and conditions set forth in this letter agreement (the “Agreement”).
INMUNE BIO INC. AMENDMENT NO. 3 TO RIGHTS AGREEMENTRights Agreement • December 18th, 2023 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • Nevada
This Amendment No. 3 (this “Amendment”), dated as of December 13, 2023, to the Rights Agreement, dated December 30, 2020, as amended on December 20, 2021 and December 9, 2022 (the “Rights Agreement”), between INmune Bio Inc., a Nevada corporation (the “Company”), and VStock Transfer LLC, as rights agent (the “Rights Agent”).
Dear Dr. Lowdell, Consultancy agreementConsultancy Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
We are writing to confirm the terms of our agreement concerning the provision of your consultancy services to Inmune Bio International Ltd. (Client).
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “First Amendment”) is made as of September 20, 2017, by and between the University of Pittsburgh – Of the Commonwealth System of Higher Education, a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania (“University”) and Immune Ventures, LLC (“Licensee”).
EXCLUSIVE LICENSE AGREEMENTLicense Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • California
IMMUNE VENTURES, LLC, a limited liability corporation organized and existing under the laws of the State of Washington, having an office and its principal place of business at 1001 4th Avenue, Suite 4500, Seattle, WA 98154 (hereinafter “Licensor”), and
ASSIGNMENT AND ASSUMPTION AGREEMENTAssignment and Assumption Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
This Assignment and Assumption ("Assignment") is effective as of October 03, 2017 ("Effective Date") by and among, Immune Ventures, LLC, a Limited Liability Company formed under the laws of the State of Washington, with principal offices located at 7503 Jones Ave NW, Seattle, WA 98116 (“ASSIGNOR”) and INmune Bio Inc., a Nevada corporation, having its principal place of business at 1224 Prospect St., Suite 150, La Jolla, CA 92037 (“ASSIGNEE”).
INMUNE BIO INC. SUBSCRIPTION AGREEMENTSubscription Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
This Subscription Agreement (the “Subscription Agreement”) is entered into by and between INmune Bio Inc., a Nevada corporation (the “Company” and/or “INmune”), and the Subscriber(s) whose name appears on the signature page to this Subscription Agreement (the “Subscriber” and, together with other subscribers to the Offering (as hereinafter defined), “Investors”).
INMUNE BIO, INC. AMENDMENT NO. 2 TO RIGHTS AGREEMENTRights Agreement • December 12th, 2022 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • Nevada
This Amendment No. 2 (this “Amendment”), dated as of December , 2022, to the Rights Agreement, dated December 30, 2020, as amended on December 20, 2021 (the “Rights Agreement”), between INmune Bio, Inc., a Nevada corporation (the “Company”), and VStock Transfer LLC, as rights agent (the “Rights Agent”).
SUBSCRIPTION AGREEMENT Common Stock of Inmune Bio Inc.Subscription Agreement • November 20th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
This subscription agreement (this “Subscription”) is dated , 2018, by and between the investor identified on the signature page hereto (the “Investor”) and Inmune Bio Inc., a Nevada corporation (the “Company”). The parties agree as follows:
Lock-Up AgreementLock-Up Agreement • October 29th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
This Lock-Up Agreement (this “Agreement”) is being delivered to Univest Securities, LLC (the “Placement Agent”) in connection with the proposed Placement Agent Agreement (the “PA Agreement”) between Inmune Bio, Inc., a Nevada corporation (the “Company”), and the Placement Agent, relating to the proposed public offering (the “Offering”) of Common Stock, par value $0.001 per share (the “Common Stock”), of the Company.
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • April 22nd, 2024 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • June 15th, 2021 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • California
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of the Effective Date among (a) SILICON VALLEY BANK, a California corporation (“SVB”), in its capacity as administrative agent and collateral agent (“Agent”), (b) SVB, as a lender, (c) SVB INNOVATION CREDIT FUND VIII, L.P., a Delaware limited partnership (“SVB Capital”), as a lender (SVB and SVB Capital and each of the other “Lenders” from time to time a party hereto are referred to herein collectively as the “Lenders” and each individually as a “Lender”), and (d) the borrower listed on Schedule I hereto (“Borrower”). The parties agree as follows:
FINANCIAL ADVISORY ENGAGEMENT AGREEMENTFinancial Advisory Engagement Agreement • March 29th, 2021 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
National Securities, Corp. (“National”) is pleased to provide on a non-exclusive basis financial advisory and investor relations services to INmune Bio, Inc. (the “Company”) with respect to 1) advising the company on ways to optimize their available financial alternatives including but not limited to the potential solicitation of new investors 2) strategic introductions, potential joint venture opportunities and assisting the Company in developing a well-coordinated and integrated plan to address ways in which the Company can seek to increase its visibility within its markets, enhance its liquidity and establish non deal roadshows and 3) any other general advisory services that the Company may seek to pursue and avail themselves of on the terms and conditions in this letter agreement (the “Agreement”).
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • April 20th, 2023 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (“First Amendment”) is made as of April 17, 2023 by and between Immune Ventures, LLC (“Licensor”) and INmune Bio, Inc., a Nevada corporation, having a principal place of business at 225 NE Mizner Blvd., STE 640, Boca Raton, FL 33432 (“Licensee”), each a “Party” and collectively the “Parties”.
